Angewandte Chemie International Edition
10.1002/anie.201802015
COMMUNICATION
To sum up, this new artemisinin synthesis uses readily available
starting materials, robust transformations along with high yields in a
minimum of reaction steps, delivering the (1´)-hydroxy artemisinic
ester derivatives 10a-d in an overall yield of 50 % over seven steps
with the possibility of performing the reactions in 10 g-scale.
Moreover, it is important to emphasize that about 90 % of the
cyclization products 10a,b,c (Scheme 2) could be transformed to the
desired artemisinin and its 9-desmethyl analogue.
[4]
W. E. Ho, H. Y. Peh, T. K. Chan, W. S. F. Wong, Pharmacol.
Therapeutics 2014, 142, 126–139.
[
5]
S. Krishna, S. Ganapathi, I. Chis Ster, M. E. M. Saeed, M. Cowan, C.
Finlayson, H. Kovacsevics, H. Jansen, P. G. Kremsner, T. Efferth, D.
Kumar, EBioMedicine 2015, 2, 82–90.
S. Krishna, L. Bustamante, R. K. Haynes, H. M. Staines, Trends
Pharmacol. Sci. 2008, 29, 520–527.
[
6]
[7]
J. Li, T. Casteels, T. Frogne, C. Ingvorsen, C. Honoré, M. Courtney, K.
V. Huber, N. Schmitner, R. A. Kimmel, R. A. Romanov, C. Sturtzel, C.
H. Lardeau, J. Klughammer, M. Farlik, S. Sdelci, A. Vieira, F. Avolio, F.
Briand, I. Baburin, P. Májek, F. M. Pauler, T. Penz, A. Stukalov, M.
Gridling, K. Parapatics, C. Barbieux, E. Berishvili, A. Spittler, J. Colinge,
K. L. Bennett, S. Hering, T. Sulpice, C. Bock, M. Distel, T. Harkany, D.
Meyer, G. Superti-Furga, P. Collombat, J. Hecksher-Sørensen, S.
Kubicek, Cell 2017, 168, 86–100.
Our convergent approach to artemisinin enables not only access to
both of its antipodes, but also paves the way for the introduction of
diverse substituents at different positions in the artemisinin
framework. For example, various alkyl or allyl groups at position 9
could be introduced whereas using different alkene-alkynes,
variations at position 3 of the natural product could be established.
Other possibilities using slight modifications in our approach are
shown in Figure 2.
[
8]
9]
A. M. Lisewski, J. P. Quiros, C. L. Ng, A. K. Adikesavan, K. Miura, N.
Putluri, R. T. Eastman, D. Scanfeld, S. J. Regenbogen, L. Altenhofen,
M. Llinás, A. Sreekumar, C. Long, D. A. Fidock, O. Lichtarge, Cell 2014,
158, 916–928.
[
[
R. K. Haynes, S. Krishna, Microb. Infect. 2004, 6, 1339–1346.
10] P. M. O’Neill, V. E. Barton, S. A. Ward, Molecules 2010, 15,
705−1721.
1
[
11] J. Wang, C. J. Zhang, W. N. Chia, C. C Y. Loh, Z. Li, Y. M. Lee, Y. He,
L. X. Yuan, T. K. Lim, M. Liu, C. X. Liew, Y. Q. Lee, J. Zhang, N. Lu, C.
T. Lim, Z. C. Hua, B. Liu, H. M. Shen, K. S. W. Tan, Q. Lin, Nat.
Commun. 2015, 6, 10111.
[
12] J. Wang, J. Zhang, Y. Shi, C. Xu, C. Zhang, Y. K. Wong, Y. M. Lee, S.
Krishna, Y. He, T. K. Lim, W. Sim, Z.-C. Hua, H. M. Shen, Q. Lin, ACS
Cent. Sci. 2017, 3, 743−750.
[
13] H. M. Ismail, V. E. Barton, M. Panchana, S. Charoensutthivarakul, G. A.
Biagini, S. A. Ward, P. M. O'Neill, Angew. Chem. Int. Ed. 2016, 55,
6401 –6405.
[
[
14] M. A. Fügi, S. Wittlin, Y. Dong, J. L. Vennerstrom, Antimicrob. Agents
Chemother. 2010, 54, 1042-1046.
15] P. M. O’Neil, S. L. Rawe, K. Borstnik, A. Miller, S. A. Ward, P. G. Bray,
J. Davies, C. H. Oh, G. H. Posner, ChemBioChem. 2005, 16, 2048–
Figure 2. Possibilities of derivatization of the (+)-artemisinin skeleton
offered by this synthesis.
2054.
[
[
[
[
16] S. Cook, Synlett, 2014, 25, 751–759.
In several Southeast Asian countries emergence of Plasmodium
falciparum strains with reduced susceptibility to artemisinins and
artemisinin combination therapy associated drugs have been
reported in the last years, resulting in increased rates of treatment
17] M. A. Corsello, N. K. Garg, Nat. Prod. Rep. 2015, 32, 359–366.
18] G. Schmid, W. Hofheinz, J. Am. Chem. Soc. 1983, 105, 624–625.
19] a) X.-X. Xu, J. Zhu, D.-Z. Huang, W.-S. Zhou, Acta Chim. Sinica 1983,
41, 574; b) X.-X. Xu, J. Zhu, D.-Z. Huang, W.-S. Zhou, Acta Chim.
[
33]
failures.
Therefore, alternatives are urgently needed and we
Sinica 1984, 42, 940; c) X.-X. Xu, J. Zhu, D.-Z. Huang, W.-S. Zhou,
Tetrahedron 1986, 42, 819-828.
believe that our results will facilitate the development of such
options. The presented method opens up the possibility of
stereospecific synthesis of new artemisinin derivatives not
accessible by existing methods. Access to enantiomeric
forms/analogs could lead to artemisinin analogs with more favorable
pharmacokinetic properties, a liability of current artemisinin analogs.
It will be also of interest to investigate the activity of (−)-artemisinin
agains other parasites like Schistosoma mansoni, Trypanosoma
cruzi and T. brucei. Eventually, our synthetic (−)-artemisinin (1) can
be used to answer the question of the stereospecificity of (+)-
[20] M. A. Avery, K. M. Chong,W. C. Jenningswhite, J. Am. Chem. Soc.
992, 114, 974–979.
1
[21] C. Zhu, S. P. Cook, J. Am. Chem. Soc. 2012, 134, 13577–13579.
[22] N. J. Acton, R. J. Roth, J. Org. Chem. 1992, 57, 3610–3614.
[23] F. Lévesque, P. H. Seeberger, Angew. Chem. Int. Ed. 2012, 51, 1706–
1709.
[
24] C. J. Paddon, P. J. Westfall, D. J. Pitera, K. Benjamin, K. Fisher, D.
McPhee, M. D. Leavell, A. Tai, A. Main, D. Eng, D. R. Polichuk, K. H.
Teoh, D. W. Reed, T. Treynor, J. Lenihan, M. Fleck, S. Bajad, G. Dang,
D. Dengrove, D. Diola, G. Dorin, K. W. Ellens, S. Fickes,J. Galazzo, S.
P. Gaucher, T. Geistlinger, R. Henry, M. Hepp, T. Horning, T. Iqbal, H.
Jiang, L. Kizer, B. Lieu, D. Melis, N. Moss, R. Regentin, S. Secrest, H.
Tsuruta, R. Vazquez, L. F. Westblade, L. Xu, M. Yu, Y. Zhang, L. Zhao,
J. Lievense, P. S. Covello, J. D. Keasling, K. K. Reiling, N. S.
Renninger, J. D. Newman, Nature 2013, 496, 528-532.
[
7]
artemisinin action on mammalian cells and proteins like gephyrin.
[
[
25] G. J. Cernigliaro, P. J. Kocienski, J. Org. Chem. 1977, 42, 3622-3624.
26] K. Tani, T. Yamagata, S. Otsuka, H. Kumobayashi, S. Akutagawa, Org.
Syntheses 1989, 67, 33-39.
Experimental Section
[
27] D. Craig, Chem. Soc. Rev. 1987, 16, 187–238.
Experimental Details.
[28] J. C. Martin, R. J. Arhar, J. Am. Chem. Soc. 1971, 93, 4327–4329.
[29] N. Acton, R. J. Roth, J. Org. Chem. 1992, 57, 3610-3614.
30] A. J. Hutt, S. C. Tan, Drugs 1996, 52, 1-12.
[
Keywords: chirality, enantiomeric drugs, ene reaction, malaria,
[31] I. Agranat, H. Caner, J. Caldwell, Nat. Rev. Drug Discov. 2001, 1, 753-
68.
7
trioxane
[
32] C. Reiter, T. Fröhlich, M. Zeino, M. Marschall, H. Bahsi, M.
Leidenberger, O. Friedrich, B. Kappes, F. Hampel, T. Efferth, S. B.
Tsogoeva, Eur. J. Med. Chem. 2015, 97, 164-172.
[
[
1]
2]
N. J. White, Science 2008, 320, 330–334.
[33] B. Blasco, D. Leroy, D. A. Fidock, Nat. Med. 2017, 23, 917-928.
N. M. Njuguna, D. S. B. Ongarora, K. Chibale, Expert Opin. Ther.
Patents 2012, 22, 1179–1203.
[
3]
Y. Tu, Angew. Chem. Int. Ed. 2016, 55, 10210–10226.
This article is protected by copyright. All rights reserved.